Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(17-(acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
2. Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)-
3. Esmeron
4. Esmerone
5. Org 9426
6. Org-9426
7. Org9426
8. Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
9. Rocuronium
10. Zemuron
1. 119302-91-9
2. Zemuron
3. Esmeron
4. Rocuronium (bromide)
5. Org 9426
6. Org-9426
7. Chebi:8885
8. I65mw4ofhz
9. 1-allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino-5alpha-androstan-16beta-yl)pyrrolidinium Bromide, 17-acetate
10. [(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] Acetate;bromide
11. Pyrrolidinium, 1-[(2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, Bromide
12. Rocuronium Hydrobromide
13. 1-[17b-(acetyloxy)-3a-hydroxy-2b-(4-morpholinyl)-5a-androstan-16b-yl]-1-(2-propenyl)pyrrolidinium Bromide
14. Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
15. Ncgc00167433-01
16. Unii-i65mw4ofhz
17. Org9426
18. Eslax
19. Rocuroniumbromide
20. Zemuron (tn)
21. Mfcd00867768
22. Rocuronium Bromide [usan:usp:inn:ban]
23. Rocuronium Bromide - Ep
24. Dsstox_cid_3566
25. Org 9426 (bromide)
26. Dsstox_rid_77083
27. Dsstox_gsid_23566
28. Schembl41320
29. (+)-rocuronium Bromide
30. Rocuronium Bromide [mi]
31. Chembl1200648
32. Dtxsid7023566
33. Rocuronium Bromide [inn]
34. Rocuronium Bromide [jan]
35. Rocuronium Bromide [usan]
36. Hms3884o13
37. Rocuronium Bromide [vandf]
38. Rocuronium Bromide [mart.]
39. Rocuronium Bromide (jan/usp/inn)
40. Rocuronium Bromide [usp-rs]
41. Rocuronium Bromide [who-dd]
42. Tox21_112437
43. Bdbm50248153
44. S1397
45. Akos025149635
46. Ac-2004
47. Ccg-270222
48. Cs-1467
49. Rocuronium Bromide [orange Book]
50. Rocuronium Bromide [ep Monograph]
51. 1-((2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidin-1-ium Bromide
52. 111ge014
53. As-13323
54. Br177300
55. Hy-17440
56. Rocuronium Bromide [usp Monograph]
57. Bcp0726000028
58. Cas-119302-91-9
59. R0099
60. D00765
61. Q-101010
62. Q27108171
63. Rocuronium Bromide, >=98% (perchloric Acid Titration)
64. Rocuronium Bromide, European Pharmacopoeia (ep) Reference Standard
65. Rocuronium Bromide, United States Pharmacopeia (usp) Reference Standard
66. Rocuronium For Peak Identification, European Pharmacopoeia (ep) Reference Standard
67. (2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-morpholin-4-yl-16-(1-prop-2-en-1-ylpyrrolidinium-1-yl)androstane Bromide
68. 1-((2s,3s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidinium Bromide
69. 1-[(2beta,3alpha,5alpha,16beta,17beta)-17-acetyloxy-3-hydroxy-2-(4-morpholinyl)-androstan-16-yl]-1(2-propenyl)pyrrolidinium Bromide
70. 1-[17beta-acetyloxy-3alpha-hydroxy-2beta-(4-morpholinyl)-5alpha-androstan-16beta-yl]-1-(2-propenyl)pyrrolidinium Bromide
71. 1-allyl-1-(3.alpha.,17.beta.-dihydroxy-2.beta.-morpholino-5.alpha.-androstan-16.beta.-yl)pyrrolidinium Bromide, 17-acetate
72. 17beta-(acetyloxy)-3alpha-hydroxy-2beta-(morpholin-4-yl)-16beta-[1-(prop-2-en-1-yl)pyrrolidinium-1-yl]-5alpha-androstane
73. 17beta-acetoxy-16beta-(1-allylpyrrolidinium-1-yl)-3alpha-hydroxy-2beta-(morpholin-4-yl)-5alphaandrostane
74. Pyrrolidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, Bromide
| Molecular Weight | 609.7 g/mol |
|---|---|
| Molecular Formula | C32H53BrN2O4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 608.31887 g/mol |
| Monoisotopic Mass | 608.31887 g/mol |
| Topological Polar Surface Area | 59 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 898 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Rocuronium bromide |
| PubMed Health | Rocuronium (Injection) |
| Drug Classes | Musculoskeletal Agent |
| Drug Label | Rocuronium bromide injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide USP is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2-(4-m... |
| Active Ingredient | Rocuronium bromide |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
| Market Status | Prescription |
| Company | Sagent Strides; Hospira; Sandoz; Teva Pharms; Fresenius Kabi Usa; Tamarang; Mylan Institutional |
| 2 of 4 | |
|---|---|
| Drug Name | Zemuron |
| Drug Label | ZEMURON (rocuronium bromide) injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2... |
| Active Ingredient | Rocuronium bromide |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
| Market Status | Prescription |
| Company | Organon Usa |
| 3 of 4 | |
|---|---|
| Drug Name | Rocuronium bromide |
| PubMed Health | Rocuronium (Injection) |
| Drug Classes | Musculoskeletal Agent |
| Drug Label | Rocuronium bromide injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide USP is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2-(4-m... |
| Active Ingredient | Rocuronium bromide |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
| Market Status | Prescription |
| Company | Sagent Strides; Hospira; Sandoz; Teva Pharms; Fresenius Kabi Usa; Tamarang; Mylan Institutional |
| 4 of 4 | |
|---|---|
| Drug Name | Zemuron |
| Drug Label | ZEMURON (rocuronium bromide) injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium bromide is chemically designated as 1-[17-(acetyloxy)-3-hydroxy-2... |
| Active Ingredient | Rocuronium bromide |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 50mg/5ml (10mg/ml); 100mg/10ml (10mg/ml) |
| Market Status | Prescription |
| Company | Organon Usa |
Neuromuscular Nondepolarizing Agents
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03A - Muscle relaxants, peripherally acting agents
M03AC - Other quaternary ammonium compounds
M03AC09 - Rocuronium bromide
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 100MG/10ML (1...DOSAGE - INJECTABLE;INJECTION - 100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20214
DOSAGE - INJECTABLE;INJECTION - 10MG/ML (10MG...DOSAGE - INJECTABLE;INJECTION - 10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20214
DOSAGE - INJECTABLE;INJECTION - 50MG/5ML (10M...DOSAGE - INJECTABLE;INJECTION - 50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20214
Related Excipient Companies
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Rocuronium Bromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rocuronium Bromide manufacturer or Rocuronium Bromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rocuronium Bromide manufacturer or Rocuronium Bromide supplier.
PharmaCompass also assists you with knowing the Rocuronium Bromide API Price utilized in the formulation of products. Rocuronium Bromide API Price is not always fixed or binding as the Rocuronium Bromide Price is obtained through a variety of data sources. The Rocuronium Bromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_3566 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_3566, including repackagers and relabelers. The FDA regulates DSSTox_CID_3566 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_3566 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_3566 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_3566 supplier is an individual or a company that provides DSSTox_CID_3566 active pharmaceutical ingredient (API) or DSSTox_CID_3566 finished formulations upon request. The DSSTox_CID_3566 suppliers may include DSSTox_CID_3566 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_3566 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_3566 DMF (Drug Master File) is a document detailing the whole manufacturing process of DSSTox_CID_3566 active pharmaceutical ingredient (API) in detail. Different forms of DSSTox_CID_3566 DMFs exist exist since differing nations have different regulations, such as DSSTox_CID_3566 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DSSTox_CID_3566 DMF submitted to regulatory agencies in the US is known as a USDMF. DSSTox_CID_3566 USDMF includes data on DSSTox_CID_3566's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DSSTox_CID_3566 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DSSTox_CID_3566 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DSSTox_CID_3566 Drug Master File in Japan (DSSTox_CID_3566 JDMF) empowers DSSTox_CID_3566 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DSSTox_CID_3566 JDMF during the approval evaluation for pharmaceutical products. At the time of DSSTox_CID_3566 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DSSTox_CID_3566 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DSSTox_CID_3566 Drug Master File in Korea (DSSTox_CID_3566 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DSSTox_CID_3566. The MFDS reviews the DSSTox_CID_3566 KDMF as part of the drug registration process and uses the information provided in the DSSTox_CID_3566 KDMF to evaluate the safety and efficacy of the drug.
After submitting a DSSTox_CID_3566 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DSSTox_CID_3566 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DSSTox_CID_3566 suppliers with KDMF on PharmaCompass.
A DSSTox_CID_3566 CEP of the European Pharmacopoeia monograph is often referred to as a DSSTox_CID_3566 Certificate of Suitability (COS). The purpose of a DSSTox_CID_3566 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DSSTox_CID_3566 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DSSTox_CID_3566 to their clients by showing that a DSSTox_CID_3566 CEP has been issued for it. The manufacturer submits a DSSTox_CID_3566 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DSSTox_CID_3566 CEP holder for the record. Additionally, the data presented in the DSSTox_CID_3566 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DSSTox_CID_3566 DMF.
A DSSTox_CID_3566 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DSSTox_CID_3566 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DSSTox_CID_3566 suppliers with CEP (COS) on PharmaCompass.
A DSSTox_CID_3566 written confirmation (DSSTox_CID_3566 WC) is an official document issued by a regulatory agency to a DSSTox_CID_3566 manufacturer, verifying that the manufacturing facility of a DSSTox_CID_3566 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DSSTox_CID_3566 APIs or DSSTox_CID_3566 finished pharmaceutical products to another nation, regulatory agencies frequently require a DSSTox_CID_3566 WC (written confirmation) as part of the regulatory process.
click here to find a list of DSSTox_CID_3566 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DSSTox_CID_3566 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DSSTox_CID_3566 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DSSTox_CID_3566 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DSSTox_CID_3566 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DSSTox_CID_3566 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DSSTox_CID_3566 suppliers with NDC on PharmaCompass.
DSSTox_CID_3566 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_3566 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_3566 GMP manufacturer or DSSTox_CID_3566 GMP API supplier for your needs.
A DSSTox_CID_3566 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_3566's compliance with DSSTox_CID_3566 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_3566 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_3566 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_3566 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_3566 EP), DSSTox_CID_3566 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_3566 USP).
